Lirum Therapeutics' LX-101 Shows Promising Preclinical Activity in Ewing Sarcoma, Advances to RAPID Platform Trial
核心洞察
Lirum Therapeutics (搜索) announced positive preclinical data for LX-101, a novel IGF-1R (搜索)-targeted therapy, demonstrating potent antitumor activity in Ewing sarcoma (搜索) patient-derived xenograft models.
The therapy showed improved activity compared to previously reported IGF-1R (搜索)-targeting approaches and demonstrated synergy when combined with PI3K (搜索) or mTOR (搜索) inhibitors.
The FDA has issued a "Study May Proceed" letter allowing LX-101's inclusion in the RAPID platform trial for patients with relapsed/refractory Ewing sarcoma (搜索) and desmoplastic small round cell tumor (搜索).
Lirum Therapeutics (搜索) announced that its lead candidate LX-101 demonstrated potent antitumor activity in preclinical models of Ewing sarcoma (搜索), with data selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego from April 17-22. The clinical-stage biopharmaceutical company reported that LX-101 showed improved preclinical activity relative to previously reported IGF-1R (搜索)-targeting approaches.
Preclinical Efficacy Data
The new data demonstrated LX-101's potent antitumor activity as a single agent in patient-derived xenograft (PDX) models of Ewing sarcoma (搜索). Additionally, the therapy showed enhanced activity, including synergy, when used in combination with PI3K (搜索) or mTOR (搜索) inhibition. According to the presentation conclusions, the observed single-agent activity and synergy with PI3K and mTOR inhibitors support further clinical development of LX-101 and LX-101-based combination strategies.
The results will be presented by Roberto Cardenas-Zuniga, a member of the research team in the lab of Joseph Ludwig, M.D., at The University of Texas MD Anderson Cancer Center, Lirum's collaborator on this project. The presentation is scheduled for April 22, 2026, from 9:00 AM to 12:00 PM PT during the session titled "Targeted Therapies, Predispositions, and Survivorship in Pediatric Cancers."
FDA Approval for Platform Trial
Lirum recently received a "Study May Proceed" letter from the FDA enabling the inclusion of LX-101 in the RAPID platform clinical trial. RAPID (Rapidly Assess Promising Innovative Drugs) is a patient-centric, multicenter, open-label platform trial led by Joseph Ludwig, M.D., professor at The University of Texas MD Anderson Cancer Center. The trial employs a master protocol that enables the study of both single-agent and novel drug combinations in patients with relapsed/refractory Ewing sarcoma (搜索) and desmoplastic small round cell tumor (搜索) (DSRCT).
Targeting IGF-1R in Ewing Sarcoma
LX-101 is a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R (搜索)), currently being developed in oncology and autoimmune indications. Ewing sarcoma (搜索) has strong ties to the IGF-1R signaling pathway, including DNA-level gene fusions such as EWSR1-FLI1 (搜索) that affect IGF-1R signaling, providing a strong scientific and clinical rationale for LX-101 in this indication.
Ewing sarcoma (搜索) is an aggressive cancer that primarily develops in the bones or surrounding soft tissues, most commonly affecting children, adolescents and young adults. It is the second most common bone cancer in children in the US and accounts for roughly 1% of childhood cancers. Current treatments are limited to a combination of chemotherapy, surgical removal of the tumors and sometimes radiation therapy.
Company Background
Founded in 2021, Lirum Therapeutics (搜索) is an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates. The company's lead candidate, LX-101, is currently being manufactured for clinical use with plans to re-enter human trials in novel oncology and autoimmune indications, including thyroid eye disease (搜索) (TED).